Latest Breaking News On - Roche zibelman - Page 1 : comparemela.com

For patients with metastatic castration-resistant prostate cancer, talazoparib combined with enzalutamide achieved better progression-free survival than enzalutamide alone.

United statesFox chase cancer centerAstellas pharmaNeeraj agarwalSelena castroMatthew zibelmanBristol myers squibbRoche zibelmanHuntsman cancer instituteUniversity of utahGenitourinary oncology programDepartment of hematology oncologyGenitourinary cancers symposiumInstituto de investigaciSouth americaAdverse events